NeuroOne® to Host Investor Call About Recent Disclosures Tomorrow March 29th at 10:00 am ET

Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on March 29, 2022, at 10:00 am ET, to discuss recent disclosures related to its 510(k) clearance request for the Evo® sEEG Electrode. This device is already cleared for temporary use of less than 24 hours and seeks approval for less than 30 days. Investors and interested parties can join via the provided dial-in numbers or access the live webcast. The call aims to clarify the recent 8-K filing and answer participant questions.

EDEN PRAIRIE, Minn., March 28, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will host a conference call to discuss recent disclosures tomorrow, March 29, 2022, at 10:00 am Eastern Time. The purpose of the call is to provide clarification and answer questions regarding disclosure included in the Company's recent Current Report on Form 8-K filed on Friday, March 25, 2022 about its 510(k) clearance request to the FDA for its Evo® sEEG Electrode for less than 30-day use. The device has already been 510(k) cleared for temporary (less than 24 hours) use.

10:00 am ET, Tuesday, March 29, 2022

Participant Dial-In: 
877-407-8293 / +1 201-689-8349
Live and archived webcast:
https://services.choruscall.com/mediaframe/webcast.html?webcastid=TiuTgwf3

Telephone Replay
877-660-6853 / 201-612-7415
End Date: 2022-04-11
Access ID: 13728487

On the call, management will answer questions submitted in advance.  To submit a question, please email questions@n1mtc.com.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. For more information, visit https://www.n1mtc.com .

View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-host-investor-call-about-recent-disclosures-tomorrow-march-29th-at-1000-am-et-301512224.html

SOURCE NeuroOne Medical Technologies Corporation

FAQ

What is the purpose of NeuroOne's conference call on March 29, 2022?

The conference call aims to discuss and clarify recent disclosures regarding the company's 510(k) clearance request for the Evo® sEEG Electrode.

What is the 510(k) clearance request related to NeuroOne?

The 510(k) clearance request pertains to the Evo® sEEG Electrode, which is currently cleared for less than 24 hours of use and is seeking approval for less than 30 days.

How can investors participate in the NeuroOne conference call?

Investors can participate by dialing in at 877-407-8293 or +1 201-689-8349, or by accessing the live webcast through the provided link.

When did NeuroOne file its recent 8-K report?

NeuroOne filed its recent 8-K report on March 25, 2022.

What time is the NeuroOne investor call scheduled for?

The NeuroOne investor call is scheduled for 10:00 am ET on March 29, 2022.